Skip Navigation LinksHome > September 2012 - Volume 112 - Issue 9 > Multiple Sclerosis Drug Fingolimod Receives New Safety Warni...
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000418919.07483.75
Drug Watch

Multiple Sclerosis Drug Fingolimod Receives New Safety Warnings Related to Cardiovascular Risk

Aschenbrenner, Diane S. MS, RN

Collapse Box

Abstract

* Fingolimod (Gilenya), a drug used in the treatment of relapsing forms of multiple sclerosis, has new labeled warnings related to the potential for serious and potentially life-threatening bradycardia.

* The risk of bradycardia is heightened in the first six hours after the initial dose, as well as between 12 and 20 hours after the first dose.

© 2012 Lippincott Williams & Wilkins, Inc.

Login